Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

This study designed to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage I lung adenocarcinoma.

Trial Details

NCT ID
NCT04591002
Phase
PHASE2
Sponsor
Samsung Medical Center
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Osimertinib 80 MG
Locations (sample)
  • Seoul, Kangnamgu, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Provision of informed consent prior to any study specific procedures
  • Adult male or female patients, aged from 30 to 75 years
  • Pathologic proven stage I lung adenocarcinoma with additional persistent GGNs in at least one other lobe: GGN is defined as a ground glass-opacity …
  • The resected lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →